Canaccord lowered the firm’s price target on Passage Bio (PASG) to $67 from $260 and keeps a Buy rating on the shares. The firm decreased its peak penetration and probability of success assumptions given the evolving competitive landscape and to await more details on the safety profile.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PASG: